Novo Nordisk (NVO) stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share on $11.92 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?Analysts polled by FactSet expected Novo to earn 83 cents a share on $11.14 billion in sales.
In the year-earlier period, Novo earned 72 cents a share and had $9.6 billion in sales.
Wegovy, the company's obesity drug, generated $2.77 billion in sales, just shy of expectations for $2.78 billion. Ozempic, the diabetes treatment that uses the same semaglutide active ingredient, brought in $4.77 billion in sales. That beat forecasts for $4.59 billion.
For the year, Novo Nordisk guided to 16% to 24% sales growth, excluding the impact of exchange rates. However, Novo noted the outlook includes expectations for "continued periodic supply constraints and related drug shortage notifications across a number of products and geographies." The Street projected earnings of $3.82 per share and $48.18 billion in sales.
In premarket trades on the stock market today, Novo Nordisk stock jumped 4% to 85.91.
More to follow.
YOU MAY ALSO LIKE:
Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Join IBD Live For Stock Ideas Each Morning Before The Open
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。